藥明康德實施首次中期分紅方案，派發現金紅利人民幣10.3億元 | Bilingual News

上海，2025年9月22日，為全球醫藥及生命科學行業提供全方位、一體化新藥研發和生產服務的能力和技術平臺公司——無錫藥明康德新藥開發股份有限公司（股票代碼：603259.SH/2359.HK）實施首次中期分紅方案，將派發現金紅利共計人民幣10.3億元。

今年以來，為提升股東價值，藥明康德通過年度分紅、特別分紅和中期分紅向投資者累計派發現金紅利共計人民幣48.8億元。公司今年已實施的現金分紅和股份回購及注銷合計達到人民幣68.8億元，占公司2024年歸母凈利潤的70%以上。

A股股東請見公司相關公告：

掃碼查看公告

H股股東請見公司相關公告：

掃碼查看公告

關于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫藥及生命科學行業值得信賴的合作伙伴和重要貢獻者，致力于通過提供一體化、端到端的新藥研發和生產服務，推動全球醫藥健康創新。公司在亞洲、歐洲、北美等地均設有運營基地，依托獨特的“CRDMO”業務模式，不斷降低研發門檻，助力客戶提升研發效率，為患者帶來突破性的治療方案。目前，公司的賦能平臺正承載著來自全球30多個國家的約6,000家合作伙伴的研發創新項目，致力于將更多新藥、好藥帶給全球病患，早日實現“讓天下沒有難做的藥，難治的病”的愿景。更多信息，請訪問公司網站：www.wuxiapptec.com

WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends

Shanghai, September 21, 2025 – WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends.

So far this year, to enhance shareholder value, WuXi AppTec has distributed a total of RMB4.88 billion in cash dividends to investors through its annual dividend, special dividend and interim dividend. The Company’s cash dividends, combined with share repurchases and cancellations implemented this year, total RMB6.88 billion, representing over 70% of the net profit attributable to the owners of the Company in 2024.

For A-share shareholders, please refer to the Company’s announcement:

Scan the QR code to view the announcement

For H share shareholders, please refer to the Company’s announcement:

Scan the QR code to view the announcement

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。